These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 19465443)

  • 21. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
    Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
    Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
    Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
    Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
    Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F; Pappalardo A; Florio C; Politi G; Fiorilla T; Reggio E; Reggio A
    Acta Neurol Scand; 2006 Apr; 113(4):241-7. PubMed ID: 16542163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.